Description: NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Home Page: www.neximmune.com
NEXI Technical Analysis
9119 Gaither Road
Gaithersburg,
MD
20877
United States
Phone:
301 825 9810
Officers
| Name | Title |
|---|---|
| Ms. Kristi Jones R.Ph. | CEO, Pres & Director |
| Mr. John Trainer M.B.A. | Chief Financial Officer |
| Dr. Jerome Bernard Zeldis M.D., Ph.D. | Exec. VP of R&D |
| Dr. Robert Douglas Knight M.D. | Chief Medical Officer |
| Dr. Mathias Oelke Ph.D. | Chief Scientific Officer |
| Dr. Jeffrey S. Weber M.D., Ph.D. | Chief Scientific Advisor, Co-Chairman of Scientific Advisory Board and Member of AI & ID SAB |
| Mr. Karen Haslbeck | Head of HR |
| Dr. Daniel P. Bednarik | Sr. VP of Molecular Engineering & Protein Design |
| Mr. Chad Rubin | Sr. VP of Corp. Affairs |
| Dr. Jack A. Ragheb M.D., Ph.D. | Sr. VP of Translational Science |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.19 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-02-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |